Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 674 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Edema Clear all
Completed Phase 4 Interventional

Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism

NCT00967304
View directory record Official record
Conditions
Idiopathic Venous Thromboembolism
Interventions
Application of the"Men continue and HER DOO2" rule
Other
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
2,779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
3
States / cities
Santa Monica, California • Rockport, Maine • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 29, 2026, 4:49 PM EDT
Not listed Phase 4 Interventional

Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension

NCT01468571
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 29, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Histamine Glutamate Antagonism in Stroke

NCT02142712
View directory record Official record
Conditions
Acute Cerebrovascular Accident, Cerebral Edema
Interventions
Diphenhydramine, Pantoprazole, Famotidine, Dextromethorphan
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 29, 2026, 4:49 PM EDT
Completed Phase 1 Interventional

Near-infrared Light (NIR) Therapy for Diabetic Macular Edema: A Pilot Study

NCT00846092
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Warp 10 LED Device, Near-infrared light (NIR)
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 29, 2026, 4:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream

NCT03899064
View directory record Official record
Conditions
Photoallergy
Interventions
Induction: Application of MC2-01 Cream, irradiation, Induction: Application of MC2-01 Cream, no irradiation, Induction: Applications of MC2-01 vehicle, irradiation, Induction: Applications of MC2-01 vehicle, no irradiation, Challenge: Application of MC2-01 Cream, irradiation, Challenge: Application of MC2-01 Cream, no irradiation, Challenge: Applications of MC2-01 vehicle, irradiation, Challenge: Applications of MC2-01 vehicle, no irradiation, Challenge: Control, irradiation
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 29, 2026, 4:49 PM EDT
Completed Phase 2 Interventional

PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)

NCT01445899
View directory record Official record
Conditions
Choroidal Neovascularization, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
PF-04523655 (Stratum I), ranibizumab, PF-04523655 (Stratum II)
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
20
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 29, 2026, 4:49 PM EDT
Enrolling by invitation Not applicable Interventional

Uncovering the Etiologies of Non-immune Hydrops Fetalis

NCT05528796
View directory record Official record
Conditions
Non-Immune Hydrops Fetalis
Interventions
Whole genome sequencing
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 29, 2026, 4:49 PM EDT
Active, not recruiting Not applicable Interventional

Research on Infarction With Open Arteries Using OCT and CMR

NCT02270359
View directory record Official record
Conditions
Myocardial Infarction
Interventions
OCT, CMR, contrast agent, Gadolinium
Device · Procedure · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 29, 2026, 4:49 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema

NCT06181227
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
AVD-104
Drug
Lead sponsor
Aviceda Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Erie, Pennsylvania • Dallas, Texas • Wichita Falls, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 29, 2026, 4:49 PM EDT
Completed Phase 3 Interventional Results available

DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME

NCT03321513
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
54
States / cities
Campbell, California • Glendale, California • Loma Linda, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 29, 2026, 4:49 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

NCT03428750
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite)
Interventions
EN3835, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
423 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
26
States / cities
Scottsdale, Arizona • Encinitas, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 29, 2026, 4:49 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Nebulized Albuterol for Congestive Heart Failure Exacerbation

NCT01375361
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Albuterol, Normal Saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2013 · Synced Oct 29, 2026, 4:49 PM EDT
Completed Phase 3 Interventional Results available

Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema

NCT00444600
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Triamcinolone Acetonide + laser, Ranibizumab + laser, Sham injection + laser, Ranibizumab + deferred laser
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
50
States / cities
Artesia, California • Beverly Hills, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 29, 2026, 4:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion

NCT01085734
View directory record Official record
Conditions
Retinal Vein Occlusions
Interventions
Avastin, Osurdex
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 29, 2026, 4:49 PM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

NCT06962839
View directory record Official record
Conditions
Macular Edema
Interventions
BI 1815368, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
36
States / cities
Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone for Lung Cancer Chemoprevention

NCT00780234
View directory record Official record
Conditions
Lung Cancer, Endobronchial Dysplasia
Interventions
fluorescence bronchoscopy, quantitative high resolution CT scan, PIOGLITAZONE VS. PLACEBO 30 mg
Procedure · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 29, 2026, 4:49 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

NCT03696784
View directory record Official record
Conditions
Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases
Interventions
iC9-CAR19 T cells, Bendamustine, Fludarabine, AP1903, Cyclophosphamide
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 29, 2026, 4:49 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

WF and PR OCTA in Diabetic Retinopathy

NCT03922932
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 29, 2026, 4:49 PM EDT
Completed Early Phase 1 Interventional Results available

Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage

NCT04088630
View directory record Official record
Conditions
Intracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic, Intracerebral Hemorrhage, Hypertensive, Intracerebral Hemorrhage Intraparenchymal
Interventions
Fingolimod, Placebo, Open-label Fingolimod
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 29, 2026, 4:49 PM EDT
Completed No phase listed Observational

International Consortium Investigating Early Vitrectomy in Diabetic Macular Edema Patients

NCT02639507
View directory record Official record
Conditions
Diabetes With Diabetic Retinopathy With Macular Edema
Interventions
Vitrectomy
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 29, 2026, 4:49 PM EDT
Completed Phase 3 Interventional Results available

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

NCT00090519
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
ruboxistaurin, placebo
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
36
States / cities
Artesia, California • Palm Springs, California • Poway, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 29, 2026, 4:49 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)

NCT03666923
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
THR-687 dose level 1, THR-687 dose level 2, THR-687 dose level 3
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 29, 2026, 4:49 PM EDT
Terminated Phase 1 Interventional Results available

Direct Peritoneal Resuscitation in Gastroschisis

NCT03205553
View directory record Official record
Conditions
Gastroschisis
Interventions
SoC Staged Silo Closure, Peritoneal Dialysis Solution/Dextrose 1.5%
Procedure · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
0 Hours to 12 Hours
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 29, 2026, 4:49 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

NCT04432831
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Faricimab, Sham Procedure
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
119
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 29, 2026, 4:49 PM EDT